Author Details

Defronzo, Ralph A, University of Texas Health Science Center, San Antonio, Texas, USA

  • Vol 15, No 2 (2015) - Editorials
    Rehabilitation of pioglitazone
    Details  HTML  PDF
  • Vol 16, No 3 (2016) - Editorials
    Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?
    Details  HTML  PDF
  • Vol 17, No 3 (2017) - Editorials
    What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?
    Details  HTML  PDF
  • Vol 20, No 1 (2020): June 2020 - Editorials
    Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives?
    Details  PDF  HTML
  • Vol 20, No 1 (2020): June 2020 - Original Research
    Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence
    Abstract  PDF  HTML